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Summary
Background Cannabis use is associated with increased risk of later psychotic disorder but whether it affects incidence 
of the disorder remains unclear. We aimed to identify patterns of cannabis use with the strongest effect on odds of 
psychotic disorder across Europe and explore whether differences in such patterns contribute to variations in the 
incidence rates of psychotic disorder.
Methods We included patients aged 18–64 years who presented to psychiatric services in 11 sites across Europe and 
Brazil with first-episode psychosis and recruited controls representative of the local populations. We applied adjusted 
logistic regression models to the data to estimate which patterns of cannabis use carried the highest odds for 
psychotic disorder. Using Europe-wide and national data on the expected concentration of Δ⁹-tetrahydrocannabinol 
(THC) in the different types of cannabis available across the sites, we divided the types of cannabis used by 
participants into two categories: low potency (THC <10%) and high potency (THC ≥10%). Assuming causality, we 
calculated the population attributable fractions (PAFs) for the patterns of cannabis use associated with the highest 
odds of psychosis and the correlation between such patterns and the incidence rates for psychotic disorder across the 
study sites.
Findings Between May 1, 2010, and April 1, 2015, we obtained data from 901 patients with first-episode psychosis 
across 11 sites and 1237 population controls from those same sites. Daily cannabis use was associated with increased 
odds of psychotic disorder compared with never users (adjusted odds ratio [OR] 3·2, 95% CI 2·2–4·1), increasing to 
nearly five-times increased odds for daily use of high-potency types of cannabis (4·8, 2·5–6·3). The PAFs calculated 
indicated that if high-potency cannabis were no longer available, 12·2% (95% CI 3·0–16·1) of cases of first-episode 
psychosis could be prevented across the 11 sites, rising to 30·3% (15·2–40·0) in London and 50·3% (27·4–66·0) in 
Amsterdam. The adjusted incident rates for psychotic disorder were positively correlated with the prevalence in 
controls across the 11 sites of use of high-potency cannabis (r = 0·7; p=0·0286) and daily use (r = 0·8; p=0·0109).
Interpretation Differences in frequency of daily cannabis use and in use of high-potency cannabis contributed to the 
striking variation in the incidence of psychotic disorder across the 11 studied sites. Given the increasing availability of 
high-potency cannabis, this has important implications for public health.
Funding source Medical Research Council, the European Community’s Seventh Framework Program grant, São Paulo 
Research Foundation, National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South 
London and Maudsley NHS Foundation Trust and King’s College London and the NIHR BRC at University College 
London, Wellcome Trust.
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Introduction
Many countries have legalised or decriminalised cannabis 
use, leading to concerns that this might result in an in­
crease in cannabis use and associated harm,1,2 even if the 
latter only affects a minority of the population.3 Cross­
sectional and prospective epidemiological studies4,5 as 
well as biological evidence6 support a causal link between 
cannabis use and psychotic disorder. Meta­analysis shows 
a dose–response association with the highest odds of 
psychotic disorder in those with the heaviest cannabis 
use.7 Nevertheless, it is not clear whether, at a population 
level, patterns of cannabis use influence rates of psychotic 
disorder.8–10
A systematic review11 has described a five­times 
variation in the incidence of schizophrenia worldwide. 
A transnational case­control study (EU­GEI) has 
reported an eight­times difference in the incidence of 
psychotic disorder across 16 European sites plus one 
in Brazil.12 Differences in the distribution of risk 
factors for psychosis, such as cannabis use, among 
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the populations studied might contribute to these 
variations.
Therefore, using data from the EU­GEI case­control 
study of first­episode psychosis and the previously 
published data on incidence,12 we sought to describe 
differences in patterns of cannabis use across sites, 
identify the measure of cannabis use with the strongest 
impact on odds of psychotic disorder across sites, 
calculate the population attributable fraction (PAF) for 
the patterns of cannabis use associated with the highest 
odds for psychosis, and test whether differences in 
patterns of cannabis use contribute to variations in the 
incidence of psychotic disorder across sites.
Methods
Study design
The EU­GEI project set out to estimate the incidence of 
psychosis and recruit first­episode psychosis cases and 
controls to investigate risk factors for psychotic 
disorder. First, incidence rates were estimated12 by 
identifying all individuals with a first episode of 
psychosis who presented to mental health services 
between May 1, 2010, and April 1, 2015, in 17 areas in 
England, France, the Netherlands, Italy, Spain, and 
Brazil (appendix). Second, to investigate risk factors, 
we attempted to assess 1000 first­episode cases and 
1000 population­based controls during the same 
period.
Participants
Patients presenting with their first episode of psychosis 
were identified by trained researchers who carried out 
regular checks across the mental health services within 
the 17 catchment areas (one site per catchment area). 
Patients were eligible if they were aged 18–64 years and 
resident within the study areas at the time of their first 
presentation with a diagnosis of psychosis by ICD­10 
criteria (F20–33); details are provided in the supple­
mentary methods and in previous publications.12 Cases 
were approached via their clinical team and invited to 
participate. Using the Operational Criteria Checklist 
algorithm, all cases interviewed received a research­
based diagnosis.13 Patients were excluded if they had 
been previously treated for psychosis or if they met 
criteria for organic psychosis (F09) or for psychotic 
symptoms resulting from acute intoxication (F1X.5).
We adopted quota sampling strategies to guide the 
recruitment of controls. Accurate local demographic data 
were used to set quotas for controls to ensure the samples’ 
representativeness of each catchment area’s population at 
risk in terms of age, gender, and ethnicity. Potential 
controls were initially identified on the basis of locally 
Research in context
Evidence before this study
The evidence reporting the dose-dependent association between 
cannabis use and psychotic disorders has been summarised in the 
meta-analysis by Marconi and colleagues. We searched PubMed 
for studies published up to March 31, 2018, that had specifically 
measured the impact of high-potency cannabis use on the odds 
of psychotic disorder (not psychotic symptoms or psychosis in 
general) or that had calculated the proportion of new cases of 
psychotic disorder arising in specific populations that were 
attributable to the use of high-potency cannabis, using the terms 
“psychotic disorders” and “high potency cannabis” or 
“skunk-super skunk” or “high THC cannabis”; we also included the 
term “population attributable fraction”. Finally, we searched for 
studies that reported the impact of any use of cannabis on the 
incidence of psychotic disorder or schizophrenia. Three studies 
met our inclusion criteria. Boydell and colleagues speculated that 
an increase in the incidence rates of schizophrenia between 1965 
and 1999 in south London might be related to the increase, over 
the same period, in the prevalence of cannabis use in the year 
before first presentation. Our two previous case-control studies 
showed that high-potency cannabis, especially when used daily, 
carries the highest risk for psychotic disorder and that, assuming 
causality, 24% of new cases of psychotic disorder in south London 
could be attributed to the use of high potency cannabis.
Added value of this study
This multicentre case-control study across ten European and 
one Brazilian site replicates the strong effect of daily use of 
high-potency cannabis on the odds for psychotic disorder in 
the whole sample—which, to our knowledge, is the largest to 
date to address this question. This effect was particularly 
visible in London and Amsterdam. Additionally, we show 
that, assuming causality, if high-potency cannabis types were 
no longer available, then 12% of cases of first-episode 
psychosis could be prevented across Europe, rising to 30% in 
London and 50% in Amsterdam. Most importantly, we 
provide the first direct evidence that cannabis use has an 
effect on variation in the incidence of psychotic disorders. 
We show that differences in the prevalence of daily use of 
cannabis, and in use of high-potency cannabis, among the 
controls from the different study sites made a major 
contribution to the striking variations in the incidence rates 
of psychotic disorder that we have previously reported across 
the same sites.
Implications of all available evidence
In the context of the well reviewed epidemiological and 
biological evidence of a causal link between heavy cannabis use 
and psychotic disorders, our findings have substantial 
implications for mental health services and public health. 
Education is needed to inform the public about the mental 
health hazards of regular use of high-potency cannabis, which is 
becoming increasingly available worldwide.
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available sampling strategies, most commonly random 
sampling from lists of all postal addresses and from 
general practitioner lists from randomly selected 
surgeries. To achieve representation of hard­to­reach 
groups (eg, young men), we then tried to oversample 
them using more ad­hoc approaches such as internet and 
newspaper advertisements, and leaflets at local stations, 
shops, and job centres. Controls were excluded if they had 
received a diagnosis of, or treatment for, psychotic 
disorder.
All participants provided informed, written consent. 
Ethical approval was provided by research ethics 
committees in each site.
Measures
We obtained sociodemographic data using the Medical 
Research Council Sociodemographic Schedule, as 
described previously.14 An updated version of the modified 
Cannabis Experience Questionnaire15 (CEQ
EU­GEI
) was used 
to gather detailed history of use of cannabis and other 
recreational drugs (appendix). To minimise recall bias, 
none of the recruitment materials for cases or controls 
mentioned cannabis or referred to its potential role as risk 
factor for psychotic disorder. Participants were asked if 
they had ever used cannabis in their lifetime; if the answer 
was yes, they were then asked to give details on their 
pattern of use. Questions on the type of cannabis used 
made no reference to its potency and allowed partici pants 
to report the colloquial name, in any language, of the 
cannabis they used.
We included six measures of cannabis use in the initial 
analyses, including lifetime cannabis use (ie, whether or 
not the individual had ever used cannabis), currently using 
cannabis, age at first use of cannabis,16 lifetime frequency 
of use (ie, the frequency that characterised the individual’s 
most consistent pattern of use), and money spent weekly 
on cannabis during their most consistent pattern of use. 
Using data published in the European Monitoring Centre 
for Drugs and Drug Addiction 2016 report17 that reported 
the concentration of Δ⁹­tetrahydrocannabinol (THC) in the 
types of cannabis available across Europe, supplemented 
by national data for each included country,18–26 we created 
the final measure of cannabis potency (appendix).
Statistical analysis
We used complete case analyses for all analyses using 
Stata version 14. We used inverse probability weights to 
account for any oversampling of controls relative to the 
populations at risk (appendix); we gave each control’s 
data a weight inversely proportional to their probability 
of selection given their key demographics (age, gender, 
and ethnicity) using census data on relevant populations. 
These weights were applied in all analyses.
To identify potential confounders, we used χ² and 
t tests to test for an association between sociodemographic 
data and the data on drug use with case­control status in 
the whole sample. On the basis of the χ² and t tests, data 
on the use of other recreational drugs were included as 
confounders in the main analyses, with low or no use 
scored as 0 and use scored as 1 in categorical variables: 
tobacco (never used or smoked <10 cigarettes per day vs 
smoked ≥10 cigarettes or more per day); stimulants, 
hallucinogens, ketamine, and novel psychoactive 
substances (so­called legal highs; never tried vs ever 
tried); and mean number of alcoholic drinks consumed 
daily on an average week. All sociodemographic and 
drug­use variables associated with case­control status 
were controlled for in all analyses (appendix).
We applied adjusted logistic regression models to 
estimate the effect of each of the six measures of cannabis 
use on the odds of a psychotic disorder (ie, case status). 
The data have a multilevel structure because cases and 
controls are nested within sites. To take account of this 
clustering in the logistic regression analysis, we used the 
cluster option in Stata. We fitted interaction terms to 
logistic models. These interaction models, using 
likelihood ratio tests, were run to investigate whether 
individual measures of cannabis use interacted with each 
other to significantly increase the odds ratios (ORs) for 
psychotic disorder and whether the ORs for psychotic 
disorder of the individual measures of cannabis use 
varied significantly by site.
The STATA punafcc command was used to calculate the 
population attributable fraction (PAF) with 95% CIs for 
the two cannabis use measures that carried the largest 
adjusted OR for psychosis. The PAF measures the 
population effect of an exposure by providing an estimate 
of the proportion of disorder that would be prevented if 
the exposure were removed, assuming causality.
To account for potential selection bias, we did a 
probabilistic sensitivity analysis using the STATA episensi 
command.27 This analysis assumes that we can assign 
prior probability distributions for the bias parameters, 
which capture the uncertainty about those parameters, 
and use these distributions in a probabilistic sensitivity 
analysis (appendix).
Finally, we used Pearson’s correlation to test for an 
association between the incidence rates for psychotic 
disorder adjusted for ethnic minority status in each site 
and the prevalence of daily cannabis use and use of high­
potency cannabis in the controls as representing the 
general population for each site.
Role of the funding source
Study funders contributed to the salaries of the re­
search workers employed but did not participate in the 
study design, data analyses, data interpretation, or 
writing of the manuscript. All authors had full access to 
the study data and had final respon sibility for the decision 
to submit for publication.
Results
Between May 1, 2010, and April 1, 2015, we ap­
proached 1519 patients with first­episode psychosis; 
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356 (23%) refused to participate, 19 (1%) could not 
consent because of language barriers, and 14 (0·9%) were 
excluded because they did not meet the age inclusion 
criteria. Patients who refused to participate were older 
(p=0·0015), more likely to be women (p=0·0063) and of 
white European origin (p<0·0001; appendix).
Thus, 1130 cases took part. These cases were broadly 
representative for gender and ethnicity of the incidence 
sample, although younger (mean age 31·2 years 
[SD 10·6], median 29 years [IQR 23–37] for cases vs mean 
34·5 years [12·0], median 31 years [23·0–41·0] for the 
total incidence; p<0·0001; details by site are available in 
the appendix). All 17 sites contributed to the recruitment 
of 1499 population controls except for Maison Blanche, 
which was con sequently excluded from the analysis 
(appendix).
Most sites had minimal missing sociodemographic 
(≤3%) or CEQEU­GEI data (<5%). However, Verona, Santiago, 
Oviedo, Valencia, and Cuenca had at least 10% of data 
missing on the measures of cannabis use or on one or 
more of the main confounding variables; therefore, given 
their small sample sizes there was insufficient data to 
include these sites in the analysis. This resulted in 
901 cases and 1237 controls for analysis.
Compared with controls, cases were younger, more 
often men, and from ethnic minorities, than the 
controls (table 1). Controls were more likely to have 
pursued higher education (p<0·0001) and to have been 
employed a year before assessment than cases 
(p<0·0001; table 1); the differences in gender, ethnicity, 
education, and employment are those expected when 
comparing patients with psychosis with general 
population samples.
More cases than controls reported having ever used 
cannabis, having smoked ten tobacco cigarettes or more 
a day, or having tried other recreational drugs (table 1). 
We found no difference between cases and controls in 
the mean number of alcoholic drinks consumed every 
day on an average week (5·2 drinks [SD 0·4] among 
controls vs 4·8 drinks [0·4] among cases; median 
2·0 drinks [IQR 0·0–6·0] for controls vs 1·0 drink 
[0·0–4·0]; p=0·45).
An adjusted logistic regression model showed that 
those who had ever used cannabis had a modest increase 
in odds of psychotic disorder compared with those who 
had never used it (table 2); the odds were slightly greater 
in those who started to use cannabis at age 15 years or 
younger.
Daily cannabis use was associated with increased odds 
of psychotic disorder compared with never having used it 
(table 2); this remained largely unchanged when taking 
into account age at first use (OR 3·1, 95% CI 2·1–5·2), 
money spent (2·9, 1·9–4·4), and type of cannabis used 
(2·6, 2·0–3·9). Those who spent €20 or more a week 
showed more than a doubling in the odds of a psychotic 
disorder (2·5, 1·6–3·8), which dropped to 1·3 (95% CI 
1·0–2·1) after controlling for daily use and type of 
cannabis used; we observed no interaction between daily 
use and money spent (p=0·67).
Use of high­potency cannabis (THC ≥10%) modestly 
increased the odds of a psychotic disorder compared with 
never use (table 2); this remained largely unchanged 
after controlling for daily use (OR 1·5, 95% CI 1·1–2·6). 
Those who had started using high­potency cannabis by 
age 15 years showed a doubling of risk (2·3, 1·4–3·1), 
without evidence of interaction (p=0·63).
Frequency of use and type of cannabis used were 
combined to generate a single­measure of frequency plus 
Controls (n=1237) Cases (n=901) p value
Age, years 36·0 (12·8) 31·2 (10·6) <0·0001
Gender ·· ·· <0·0001
Female 655 (53·0%) 343 (38·1%) ··
Male 582 (47·0%) 558 (61·9%) ··
Self-reported ethnicity ·· ·· <0·0001
White 930 (75·2%) 532 (59·0%) ··
Black 118 (9·5%) 168 (18·6%) ··
Mixed 113 (9·1%) 104 (11·5%) ··
Asian 33 (2·7%) 32 (3·6%) ··
North African 23 (1·9%) 42 (4·7%) ··
Others 20 (1·6%) 23 (2·6%) ··
Education ·· ·· <0·0001
School with no qualifications 66 (5·3%) 158 (17·5%) ··
School qualifications 159 (12·9%) 232 (25·7%) ··
Vocational or undergraduate 826 (66·8%) 465 (51·6%) ··
Postgraduate 177 (14·3%) 36 (4·0%) ··
Data missing 9 (0·7%) 10 (1·1%) ··
Employment status 1 year before assessment ·· ·· <0·0001
Unemployed 95 (7·7%) 169 (18·8%) ··
Economically inactive (ie, house person) 122 (9·9%) 62 (6·9%) ··
Student 215 (17·4%) 146 (16·2%) ··
Employee (full time/part time/self-employed) 805 (65·1%) 488 (54·2%) ··
Data missing 0 36 (4·0%) ··
Lifetime cannabis use ·· ·· <0·001
Yes 574 (46·4%) 585 (64·9%) ··
No 650 (52·5%) 303 (33·6%) ··
Data missing 13 (1·1%) 13 (1·4%) ··
Lifetime tobacco use ·· ·· <0·0001
Smokes ≥10 cigarettes per day 158 (12·8%) 296 (32·9%) ··
Smokes <10 cigarettes per day 238 (19·2%) 182 (20·1%) ··
Never used 838 (67·8%) 421 (46·8%) ··
Data missing 3 (0·2%) 2 (0·2%) ··
Lifetime use of other drugs
Legal highs 30 (2·4%) 39 (4·3%) 0·0142
Stimulants 149 (12·0%) 196 (21·8%) <0·0001
Hallucinogens 111 (9·0%) 131 (14·5%) <0·0001
Ketamine 35 (2·8%) 55 (6·1%) 0·0002
Data missing 2 (0·2%) 0 ··
Data are n (%) or mean (SD).
Table 1: Sociodemographics and lifetime history of substance misuse across all included cases and controls
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type of use because these two measures had the highest 
ORs. Adjusted logistic regression indicated that daily use 
of high­potency cannabis carried more than a four­times 
increase in the risk of psychotic disorder (OR 4·8, 95% CI 
2·5–6·3) compared with never having used cannabis; the 
odds were lower for those who used low­potency cannabis 
daily (2·2, 1·4–3·6; figure 1). Nevertheless, there was no 
evidence of interaction between frequency of use and 
type of cannabis used (p=0·25).
When considering variation by site, neither the ORs 
for daily use (p=0·25) nor those for high­potency 
cannabis (p=0·45), compared with never use, varied 
significantly across sites (table 3). The observed 
differences in ORs for daily use ranged from 7·1 (95% CI 
3·4–11·8) in Amsterdam to 1·1 (0·4–12·2) in 
Puy de Dôme. Similarly, the differences in the ORs for 
use of high­potency cannabis, ranging from 3·6 
(1·5–7·7) in Amsterdam to 0·6 (0·1–2·5) in Palermo, are 
consistent with the geographical differences in its 
availability.17
In the three sites with the greatest consumption of 
high­potency cannabis, daily use of high­potency 
Controls (n=1237) Cases (n=901) p value* Crude OR 
(95% CI)†
p value Fully adjusted 
OR (95% CI)†
p value
Lifetime cannabis use‡ .. .. <0·0001
No 650 (52·5%) 303 (33·6%) ·· 1 (ref) ·· 1 (ref) ··
Yes 574 (46·4%) 585 (64·9%) .. 2·45 (2·0–2·9) <0·0001 1·3 (1·1–1·6) 0·0225
Currently using cannabis 132 (10·7%) 198 (22·0%) 0·00349 2·7 (2·1–3·5) <0·0001 1·1 (0·9–1·5) 0·36
First used cannabis age ≤15 years old 169 (13·7%) 257 (28·6%) <0·0001 3·9 (3·0–4·9) <0·0001 1·6 (1·1–2·1) 0·0122
Lifetime frequency of use .. .. <0·0001
Never or occasional use 1061 (85·8%) 528 (58·7%) ·· 1 (ref) ·· 1 (ref) ··
Used more than once a week 92 (7·4%) 107 (11·9%) .. 2·5 (1·9–3·5) <0·0001 1·4 (1·0–2·0) 0·066
Daily use 84 (6·8%) 266 (29·5%) ·· 6·2 (4·8–8·2) <0·0001 3·2 (2·2–4·1) <0·0001
Spent at least €20 per week on cannabis 40 (3·2%) 156 (17·4%) <0·0001 5·6 (4·0–7·7) <0·0001 2·5 (1·6–3·8) <0·0001
Lifetime use of cannabis by potency§ .. .. <0·0001
Low potency (THC <10%) 331 (26·7%) 251 (27·9%) .. 2·0 (1·6–2·5) <0·0001 1·1 (0·9–1·5) 0·38
High potency (THC ≥10%) 240 (19·4%) 334 (37·1%) ·· 3·2 (2·6–4·0) <0·0001 1·6 (1·2–2·2) 0·0032
Crude ORs are adjusted only for age, gender, and ethnicity whereas fully adjusted ORs are additionally adjusted for level of education, employment status, tobacco, stimulants, 
ketamine, legal highs, and hallucinogenics. OR=odds ratio. THC=Δ⁹-tetrahydrocannabinol. *p value for χ² test. †Reference group for both crude and adjusted ORs is the never 
users unless specified otherwise. ‡Data were missing for 13 individuals in each group. §Data were missing for three controls.
Table 2: Measure of cannabis use and ORs for psychotic disorders for case-control sample across 11 sites
Figure 1: Crude and fully adjusted ORs of psychotic disorders for the combined measure of frequency plus type of cannabis use in the whole sample
Crude ORs are adjusted only for age, gender and ethnicity and fully adjusted ORs are additionally adjusted for level of education, employment status, and use of 
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cannabis was associated with the greatest increase in the 
odds for psychotic disorder compared with never having 
used: four times greater in Paris, five times greater in 
London, and more than nine times greater in Amsterdam 
(figure 2).
Based on the prevalence of daily cannabis use, and 
use of high potency cannabis, in cases and controls and 
the corresponding adjusted ORs, we estimated the 
PAFs for the whole sample and for each of the sites 
(table 3). Assuming causality, the proportion of new 
cases of psychotic disorder in the whole sample 
attributable to daily use was 20·4% (95% CI 17·6–22·0) 
and 12·2% (3·0–6·1) for use of high­potency cannabis 
(table 3).
The PAF analysis revealed variations by sites, ranging 
from 43·8% (95% CI 34·0–69·1) of new cases of 
psychotic disorder in Amsterdam being attributable to 
daily use to just 1·2% (0·8–15·4) of cases in Puy de Dôme. 
Furthermore, the PAF for use of high­potency cannabis 
ranged from 50·3% (27·4–66·0) of cases in Amsterdam 
to 1·9% (0·6–16·3) estimated in Bologna. We did not 
calculate the PAF for Palermo because there was no 
main effect of use of high­potency cannabis on the odds 
for psychotic disorder.
The probabilistic sensitivity analyses we ran suggest 
that selection bias is unlikely to explain our findings 
(appendix). After correction for selection bias, the OR for 
daily cannabis use (5·7, 95% CI 3·5–9·4) was similar to 
the original OR (5·7, 4·4–7·5). However, the CI for the 
corrected OR was wider than that for the original OR, 
suggesting a wider range of possible values for the true 
OR with 95% certainty. The results of the probabilistic 
sensitivity analysis to estimate the potential effects of 
selection bias on high potency cannabis use  were similar 
(appendix).
The EU­GEI incidence study reported an eight­times 
variation in the incidence rates of psychotic disorder 
adjusted for age, gender, and ethnic minority status 
across the study sites.12 We found a correlation between 
the adjusted incidence rates for psychotic disorder in 
our 11 sites and the prevalence of daily cannabis use in 
controls (r=0·8; p=0·0109). Sites where daily use was 
common such as London (26 [11·7%] of 223 controls) 
and Amsterdam (13 [13·0%] of 100 controls) had among 
the highest adjusted incidence rates (45·7 cases 
per 100 000 person­years in London and 37·9 per 
100 000 person­years in Amsterdam). This differed from 
sites such as Bologna where daily use was less frequent 
(three [4·6%] of 65 controls) and the adjusted in­
cidence rate was half that of London (21·0  cases per 
100 000 per person years; figure 3).
Similarly, we found a correlation between adjusted 
incidence rates for psychotic disorder and the prevalence 
of use of high­potency cannabis in controls across the 
11 sites (r=0·7; p=0·0286). Amsterdam (54 [54·0%] of 
100 controls), London (58 [26·0%] of 223 controls), and 
Paris (21 [21·0%] of 100 controls) had the highest 
prevalence of use of high­potency cannabis in controls 
and the highest adjusted incidence rates for all psychosis 
(45·7 per 100 000 person­years in London, 37·9 in 
Amsterdam, and 46·1 in Paris; figure 3). The prevalence 
of daily use and the prevalence of use of high­potency 
cannabis in controls were only modestly correlated 
(r=0·2; p=0·0413), therefore we report data for both 
(figure 3).
Discussion
Our main findings show that among the measures of 
cannabis use tested, the strongest independent 
predictors of whether any given individual would have 
a psychotic disorder or not were daily use of cannabis 
and use of high­potency cannabis. The odds of 
psychotic disorder among daily cannabis users were 
3·2 times higher than for never users, whereas the 
odds among users of high­potency cannabis were 
1·6 times higher than for never users. Starting to use 
cannabis by 15 years of age modestly increased the 
odds for psychotic disorder but not independently of 









High-potency cannabis (THC ≥10%)
Whole sample 1·6 (1·2–2·2) 19·1% 35·1% 12·2% (3·0–16·1)*
London (UK) 2·4 (1·4–4·0) 26·0% 51·5% 30·3% (15·2–40·0)*
Cambridge (UK) 1·3 (0·4–4·3) 11·0% 34·7% 8·2% (0·5–18·7)
Amsterdam (Netherlands) 3·6 (1·5–7·7) 54·0% 69·6% 50·3% (27·4–66·0)*
Gouda and Voorhout 
(Netherlands)
1·5 (0·8–3·1) 18·2% 36·0% 12·2% (8·7–25·3)*
Paris (Val-de-Marne; France) 2·1 (0·8–3·6) 21·0% 35·9% 18·9% (14·6–36·0)*
Puy de Dôme (France) 1·5 (0·4–5·8) 3·7% 7·1% 2·3% (0·6–17·2)
Madrid (Spain) 2·0 (0·7–5·7) 15·1% 34·0% 17·2% (0·9–25·0)
Barcelona (Spain) 1·6 (0·5–5·1) 7·8% 13·2% 4·7% (0·5–12·4)
Bologna (Italy) 1·2 (0·8–1·7) 8·7% 11·1% 1·9% (0·6–16·3)
Palermo (Italy) 0·6 (0·1–2·5) 5·2% 4·3% Not calculated
Ribeirão Preto (Brazil) 2·1 (0·6–11·3) 1·5% 3·6% 1·9% (0·3–4·1)
Daily cannabis use
Whole sample 3·2 (2·2–4·1) 6·8% 29·5% 20·4% (17·6–22·0)*
London (UK) 3·6 (1·4–4·4) 11·7% 29·0% 21·0% (11·1–31·2)*
Cambridge (UK) 2·2 (0·8–6·5) 4·0% 20·2% 10·4% (4·7–21·0)*
Amsterdam (Netherlands) 7·1 (3·4–11·8) 13·1% 51·0% 43·8% (34·0–69·1)*
Gouda and Voorhout 
(Netherlands)
2·8 (1·4–20·3) 6·0% 27·0% 17·4% (1·1–23·1)*
Paris (Val-de-Marne; France) 2·8 (1·7–12·3) 11·6% 32·3% 20·8% (13·5–36·1)*
Puy de Dôme (France) 1·1 (0·4–12·2) 6·0% 11·0% 1·2% (0·8–15·4)
Madrid (Spain) 2·5 (2·1–7·3) 10·5% 21·2% 12·7% (3·7–14·2)*
Barcelona (Spain) 1·8 (0·8–8·7) 8·3% 18·9% 8·6% (0·6–9·9)
Bologna (Italy) 2·0 (0·5–5·8) 4·1% 17·3% 8·2% (0·8–11·7)
Palermo (Italy) 1·7 (0·7–9·7) 5·1% 17·1% 6·3% (0·9–21·1)
Ribeirão Preto (Brazil) 2·4 (1·5–7·5) 7·4% 25·0% 14·5% (10·2–24·1)*
OR=odds ratio. PAF=population attributable fraction. *p<0·05.
Table 3: PAFs for daily use of cannabis and use of high-potency cannabis in the whole sample and by site
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frequency of use or of the potency of the cannabis 
used. These measures of extent of exposure did not 
interact with each other, nor did they interact with the 
sites. This lack of interaction between degree of 
cannabis use (ie, daily use of cannabis or use of high­
potency cannabis) and site might reflect insufficient 
power in our study; however, it could also indicate 
that although the magnitude of the effect might vary 
depending on the degree of cannabis use, there is a 
consistent effect of daily use and use of high­potency 
cannabis on the ORs for psychotic disorders across all 
study sites.
We replicated our previous finding28 that daily use of 
high­potency cannabis is most strongly associated with 
case­control status. Compared with never users, par­
ticipants who used high­potency cannabis daily had four­
times higher odds of psychosis in the whole sample, with 
a five­times increase in London and a nine­times increase 
in Amsterdam. We also saw that, in the whole sample, 
daily use of high­potency cannabis was associated with a 
doubling in the OR for psychotic disorder. The large 
sample size and the different types of cannabis available 
across Europe have allowed us to report that the dose–
response relationship characterising the association 
between cannabis use and psychosis7 reflects not only the 
use of high­potency cannabis but also the daily use of 
types with an amount of THC consistent with more 
traditional varieties.
Use of high­potency cannabis was a strong predictor 
of psychotic disorder in Amsterdam, London, and Paris 
where high­potency cannabis was widely available, by 
contrast with sites such as Palermo where this type was 
not yet available. In the Netherlands, the THC content 
reaches up to 67% in Nederhasj and 22% in Nederwiet; 
in London, skunk­like cannabis (average THC of 14%) 
represents 94% of the street market29 whereas in 
countries like Italy, France, and Spain, herbal types of 
cannabis with THC content of less than 10% were still 
commonly used.17,18
Thus our findings are consistent with previous 
epidemiological and experimental evidence suggesting 
that the use of cannabis with a high concentration of 
THC has more harmful effects on mental health than 
does use of weaker forms.28,30,31
The novelty of this study is its multicentre structure 
and the availability of incidence rates for psychotic 
disorder for all the sites. This has allowed us, for the first 
time, to show how the association between cannabis use 
and risk of psychosis varies geographically depending on 
prevailing patterns of use, and how the latter contributes 
to variation in incidence rates for psychotic disorder.
Variations in patterns of cannabis use across the sites 
translated into differences in the proportion of new 
cases of psychotic disorder attributable to cannabis use. 
We estimated, assuming causality, that 20% of new 
cases of psychotic disorder across all our sites could 
have been prevented if daily use of cannabis had been 
abolished; the PAF for daily use was 21% for London, 
similar to that previously reported,3 but ranged from 
44% in Amsterdam to 6% in Palermo. The local 
Figure 2: Fully adjusted ORs of psychotic disorders for the combined measure of frequency plus type of cannabis use in three sites
Data are shown for the three sites with the greatest consumption of cannabis: London (201 cases, 230 controls), Amsterdam (96 cases, 101 controls), and Paris 
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availability of high­potency types of cannabis resulted in 
a PAF of 50% for Amsterdam and 30% for London. 
Therefore, assuming causality, if high­potency cannabis 
were no longer accessible, the adjusted incidence rates 
for all psychotic disorder in Amsterdam would drop 
from 37·9 to 18·8 cases per 100 000 person­years and in 
London from 45·7 to 31·9 cases per 100 000 person­
years.
Finally, we report what, to our knowledge, is the first 
evidence that differences in the prevalence of daily use 
and use of high­potency cannabis in the controls correlate 
with the variation in the adjusted incidence rates for 
psychotic disorder across the study sites. Our results 
show that in areas where daily use and use of high­
potency cannabis are more prevalent in the general 
population, there is an excess of cases of psychotic 
disorder.
Our findings need to be appraised in the context of 
limitations. Data on cannabis use are not validated by 
biological measures, such as urine, blood, or hair samples. 
However, such measures do not allow testing for use over 
previous years.26 Moreover, studies with laboratory data 
and self­reported information have shown that cannabis 
users reliably report frequency of use and the type of 
cannabis used.32,33
Our potency variable does not include the proportion 
of another important cannabinoid, cannabidiol (CBD),34 
because reliable data on this were available for only 
England and Holland.17,19,24,25,34 We categorised the 
reported types of cannabis used as low and high potency 
on the basis of the available estimates of mean 
percentage of THC from official sources. Although this 
approach does not account for variations in the THC 
content in individual samples, we used a conservative 
cutoff of 10%. Given the much higher mean percentage 
of THC expected in types of cannabis commonly 
used in UK24,29 and in Holland,19 our dichotomous 
categorisation might have led to under estimation of the 
effect of potency on the ORs for psychotic disorder. 
Furthermore, a direct measure of the THC content of 
the cannabis samples used by our participants would 
have only provided data on THC value for a single 
timepoint rather than an estimate covering lifetime 
use.
When setting quotas based on the main sociodemo­
graphics of the populations at risk for the recruitment of 
controls, we applied weights to account for under­
sampling or oversampling of some groups. For instance, 
most of the sites oversampled the age group 16–24 years 
(appendix), which represents the part of the population 
most likely to consume cannabis17 and the most likely to 
suffer associated harm.6,16,35
Moreover, none of the sites mentioned either cannabis, 
or other, drug use in the materials used for participant 
recruitment, thus avoiding selection and recall bias. 
First­episode studies minimise the effect of recall bias, 
which can be a source of error when history of exposure 
to environmental factors is collected retrospectively in 
patients with well established psychosis. This study 
design also reduces the chances of results being biased 
by illness course; therefore, it is preferred to investigate 
aetiology.36
In conclusion, our findings confirm previous evidence 
of the harmful effect on mental health of daily use of 
cannabis, especially of high­potency types. Importantly, 
they indicate for the first time how cannabis use affects 
the incidence of psychotic disorder. Therefore, it is of 
Figure 3: Adjusted incidence rates for all psychosis for the 11 sites plotted 
against the prevalence of daily use in the population controls (A) and 
prevalence of use of high-potency cannabis in the population controls (B)
Incidence rates are adjusted for age, gender, and ethnicity. Puy-de-Dôme is not 
included because data on ethnicity were missing for 27 (66%) of 42 incidence 
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public health importance to acknowledge alongside 
the potential medicinal properties of some cannabis 
constituents the potential adverse effects that are 
associated with daily cannabis use, especially of high­
potency varieties.
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